GlassScriptPhysician profile
Joseph S Cervone
NPI 1710991187
$12,090.92
in general payments reported to CMS, 2019-2025
48 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,767 · 2020: $3,739 · 2021: $640 · 2022: $536 · 2023: $881 · 2024: $606 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,409.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,038.58 | 2019-2025 | |
| Novo Nordisk INC | $2,105.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $894.18 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $596.42 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.72 | 2019-2025 | Jardiance |
| Abbvie INC. | $385.43 | 2019-2025 | Vraylar, Ubrelvy |
| Merck Sharp & Dohme LLC | $352.71 | 2019-2021 | |
| Lilly USA, LLC | $305.61 | 2019-2025 | Zepbound, Kisunla, Mounjaro |
| Novartis Pharmaceuticals Corporation | $289.65 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $258.67 | 2019-2020 | |
| Amarin Pharma, INC. | $251.14 | 2019-2023 | |
| Glaxosmithkline, LLC. | $194.35 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $192.07 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $182.25 | 2023-2025 | |
| Exact Sciences Corporation | $176.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cervone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.